IDXX Idexx Laboratories
FY2025 10-K
Idexx Laboratories (IDXX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 20, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Provider of veterinary diagnostics, software, services, and water testing solutions with recurring consumable sales and instrument placements
- • New product emphasis: Launch and sales growth of IDEXX inVue Dx Analyzer driving 51.8% increase in instrument revenue for Companion Animal Group
Management Discussion & Analysis
- • Revenue $3.52B, up 9% YoY from $3.23B in prior year driven by Companion Animal Group growth
- • Operating margin 25.3% vs 24.1% prior year reflecting scale and efficiency gains
Risk Factors
- • Tariff risk from changing U.S. and retaliatory tariffs increasing production costs and reducing profit margins on 36% of revenue from international sales
- • Global sales exposure with 36% revenue from over 175 countries vulnerable to adverse trade policy shifts
Financial SummaryXBRL
Revenue
$4.3B
Net Income
$1.1B
Gross Margin
61.8%
Operating Margin
31.6%
Net Margin
24.6%
ROE
66.0%
Total Assets
$3.4B
EPS (Diluted)
$13.08
Operating Cash Flow
$1.2B
Source: XBRL data from Idexx Laboratories FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Idexx Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.